5-Amino-1MQ
5-Amino-1-methylquinolinium
A small molecule NNMT inhibitor that raises intracellular NAD+ by blocking its consumption in fat cells. Early animal research shows significant fat mass reduction and improved metabolic markers.
5-Amino-1MQ is not approved by the FDA for human use. It is sold strictly for research purposes only and is not intended for human consumption, diagnosis, treatment, or prevention of any disease or condition. Purchase and use is entirely at your own risk.
Sourcing for research purposes?
View at Ascension Peptides →What it is
5-Amino-1MQ (5-Amino-1-methylquinolinium) is a small molecule that inhibits NNMT — Nicotinamide N-methyltransferase. NNMT is an enzyme that consumes NAD+ (indirectly via SAM) and is significantly upregulated in the fat cells of obese individuals.
By blocking NNMT, 5-Amino-1MQ raises intracellular NAD+ levels and reactivates metabolic pathways that become suppressed in obesity. The mechanism is complementary to — but distinct from — NAD+ precursors like NMN and NR, which increase NAD+ by providing more substrate. 5-Amino-1MQ instead reduces NAD+ consumption by blocking one of its metabolizing enzymes.
It is a small molecule, not a peptide, but is frequently grouped in the same biohacking and metabolic optimization space.
What research shows
- Significant reduction in fat cell size and fat mass in diet-induced obese mouse models
- Increased NAD+ levels in adipose tissue following NNMT inhibition
- Improved insulin sensitivity and glucose metabolism in obese animal models
- Activation of SIRT1 — a key longevity-associated enzyme dependent on adequate NAD+
- No significant muscle loss observed alongside fat mass reduction in animal studies
What remains unknown
- Human safety and efficacy — no published human clinical trials exist
- Long-term effects — NNMT plays roles in multiple physiological systems beyond fat metabolism
- Optimal human dose and dosing frequency
- Whether effects observed in obese animal models translate to metabolically normal individuals
- Full interaction profile with medications and other compounds
Administration basics
Common use cases
Fat loss support, metabolic optimization, NAD+ pathway enhancement. Often used alongside NAD+ precursors for a combined approach.
Half-life
Not established in humans. Limited pharmacokinetic data from animal studies only.
Administration
Oral capsule or sublingual. Notable for oral bioavailability — a significant practical advantage over injectable compounds.
Source this compound
Looking for 5-Amino-1MQ?
Ascension Peptides is a third-party research compound vendor. We link to them as an affiliate — if you purchase through our link we may earn a commission at no cost to you. All compounds are sold for research purposes only and are not intended for human use.
View at Ascension PeptidesResearch Protocols & Common Usage
Doses used in research
- Animal study doses do not translate directly to human equivalents
- Community protocols commonly report 50–100mg per day orally, though this has no clinical basis
- Some reports of twice-daily dosing (morning and midday) in an attempt to maintain levels throughout the day
Administration routes studied
Typical protocol duration
Community protocols typically report 8–12 week cycles. Long-term safety is entirely unknown.
Common stacking protocols
- 5-Amino-1MQ + NMN or NR — combined to raise NAD+ through both increased precursor supply and reduced consumption; considered mechanistically synergistic
- 5-Amino-1MQ + Berberine — combined for broad metabolic support via AMPK and NAD+ pathways
- 5-Amino-1MQ + Metformin — combined for multi-mechanism metabolic optimization; both affect glucose metabolism
- 5-Amino-1MQ + Semaglutide/Tirzepatide — some research interest in combining NNMT inhibition with GLP-1 agonists for enhanced fat loss
Contraindications & combinations to avoid
- No established human contraindication profile — human trial data is absent
- Liver disease — NNMT is highly expressed in the liver; implications of inhibition at this site are not well characterized
- Pregnancy and breastfeeding — no safety data; avoid
- Oncology context — NNMT plays complex roles in cancer biology; the implications of inhibition are not clearly defined and could be bidirectional
Dosing information reflects doses used in published research and commonly reported community protocols only. This is not a personal recommendation. These compounds are not FDA-approved for human use in the contexts described. Consult a qualified healthcare provider before starting any protocol.
Considering stacking?
See the stacking guide for common combinations with 5-Amino-1MQ and what to avoid.
Track your 5-Amino-1MQ protocol
Log your experience, track outcomes over time, and get AI-powered interpretation of your results after 14 days of data. Private, $14.99/month.
Start trackingGet research updates
We'll notify you when we update the 5-Amino-1MQ page or publish related research.
More in the library
Community Reviews
Reviews reflect individual user experiences with research compounds and are not medical advice. Results vary. These compounds are not FDA approved for human use. Peptelligent does not verify reported experiences.
Write a Review
No reviews yet. Be the first to share your experience.